This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Genzyme Corporation. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Alaa Hamed: Innovator in Pompe Disease Treatment
Introduction
Alaa Hamed is a notable inventor based in Chestnut Hill, MA (US). He has made significant contributions to the field of medicine, particularly in the treatment of late-onset Pompe disease. His innovative work has led to the development of a pharmaceutical composition that offers new hope for patients suffering from this condition.
Latest Patents
Alaa Hamed holds a patent for "Compositions and methods for treating late-onset Pompe disease." This patent describes methods of treating late-onset Pompe disease (LOPD) using a pharmaceutical composition comprising an oligosaccharide-acid α-glucosidase (GAA) conjugate, such as avalglucosidase alfa. This invention represents a significant advancement in the therapeutic options available for managing this rare genetic disorder.
Career Highlights
Alaa Hamed is currently associated with Genzyme Corporation, a leading biotechnology company known for its focus on rare diseases. His work at Genzyme has allowed him to collaborate with other experts in the field and contribute to groundbreaking research and development.
Collaborations
Alaa has worked alongside talented colleagues, including Patrick Finn and Catherine Wilson. Their combined expertise has fostered an environment of innovation and collaboration, leading to advancements in treatments for rare diseases.
Conclusion
Alaa Hamed's contributions to the treatment of late-onset Pompe disease highlight his role as a key innovator in the medical field. His patent and work at Genzyme Corporation demonstrate his commitment to improving patient outcomes through innovative solutions.